Hunan Aslsen Technology (revision 56)

Hunan Aslsen Technology Co., Ltd. (trading as Homopeptide; homopeptide.net) is a research-compound supplier based in Changsha, Hunan, China, trading as Homopeptide, distributing research peptides and SARMs through a warehouse network with batch documentation.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

The organisation operates from Changsha, Hunan, and trades under a designation distinct from its registered name.^[1] No incorporation year is documented in sources available to this wiki and none is asserted here.

Changsha is inland, and as with the Chengdu and Xi'an entities that has consequences for transit and cold-chain exposure on China-origin shipments. Purchaser reports also describe fulfilment from regional warehouses, so the origin of a given order has not been predictable.^[5]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material with a batch certificate reporting purity and appearance. Water figures and method statements have been largely absent from the submitted set.^[5][6]

Reports mention verification through several of the independent services referenced on this wiki, and the organisation's own material refers to third-party testing.^[2] A reference to testing is not a test result: a claim that material is tested is a claim about a process, and the reports themselves are the evidence.^[5]

The catalogue is narrower than most covered here. Documentation in the submitted set has been consistently thin, without the peptide-versus-bulk gradient visible elsewhere.^[5]

Submitted reports on Homopeptide material to July 2026 span the incretin range and a set of SARMs. Reported area percent figures have been more dispersed than for the better-documented entities, with a visible proportion below the high-nineties cluster.^[5]

Two limitations compound here. Without a method statement on the certificate, a disagreement between certificate and report cannot be attributed to the material or to the separation. Without a water figure, no reported purity can be converted into a mass. The reports therefore constrain the material less than their number suggests.^[6]

An additional observation from the set: several reports concerned SARM rather than peptide material, for which area percent by ultraviolet detection is a less informative measure than for a peptide, because a small-molecule impurity may not absorb at the wavelength used.^[6]

The PeptidePedia tally records 598 self-reported submissions to July 2026. Recurring complaints concern documentation depth, variance between orders and unpredictable shipping origin; recurring positive themes are price and, from regional stock, delivery speed.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

• Visit Homopeptide

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.